Literature DB >> 17967864

Nonpathogenic Escherichia coli strain Nissle 1917 inhibits signal transduction in intestinal epithelial cells.

Nobuhiko Kamada1, Kenichi Maeda, Nagamu Inoue, Tadakazu Hisamatsu, Susumu Okamoto, Kyong Su Hong, Takaya Yamada, Noriaki Watanabe, Kanji Tsuchimoto, Haruhiko Ogata, Toshifumi Hibi.   

Abstract

Although the probiotic Escherichia coli strain Nissle 1917 has been used for the treatment of inflammatory bowel diseases, the precise mechanisms of action of this strain remain unclear. In the present study, we estimated the anti-inflammatory effect of E. coli Nissle 1917 on inflammatory responses in vitro to determine the suppressive mechanism of Nissle 1917 on the inflammatory process. To determine the effect of E. coli Nissle 1917, the human colonic epithelial cell line HCT15 was incubated with or without E. coli Nissle 1917 or another nonpathogenic E. coli strain, K-12, and then tumor necrosis factor alpha (TNF-alpha)-induced interleukin-8 (IL-8) production from HCT15 cells was assessed. Enzyme-linked immunosorbent assays and real-time quantitative PCR showed that Nissle 1917 treatment suppressed TNF-alpha-induced IL-8 transcription and production. In addition, results from luciferase assays indicated that Nissle 1917 inhibited IL-8 promoter activity. On the other hand, these anti-inflammatory effects were not seen with E. coli K-12. In addition, heat-killed Nissle 1917 or its genomic DNA did not have this anti-inflammatory effect. Surprisingly, Nissle 1917 did not affect IL-8 transactivation pathways, such as NF-kappaB activation, nuclear translocation, and DNA binding, or even activation of other transcriptional factors. Furthermore, it also became evident that Nissle 1917 induced the anti-inflammatory effect without contact to epithelial cells. In conclusion, these data indicate that the nonpathogenic E. coli strain Nissle 1917 expresses a direct anti-inflammatory activity on human epithelial cells via a secreted factor which suppresses TNF-alpha-induced IL-8 transactivation through mechanisms different from NF-kappaB inhibition.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17967864      PMCID: PMC2223654          DOI: 10.1128/IAI.01193-07

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  31 in total

1.  Prokaryotic regulation of epithelial responses by inhibition of IkappaB-alpha ubiquitination.

Authors:  A S Neish; A T Gewirtz; H Zeng; A N Young; M E Hobert; V Karmali; A S Rao; J L Madara
Journal:  Science       Date:  2000-09-01       Impact factor: 47.728

Review 2.  Inflammatory bowel disease.

Authors:  Daniel K Podolsky
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

Review 3.  Paneth cells, defensins, and the commensal microbiota: a hypothesis on intimate interplay at the intestinal mucosa.

Authors:  Nita H Salzman; Mark A Underwood; Charles L Bevins
Journal:  Semin Immunol       Date:  2007-05-07       Impact factor: 11.130

Review 4.  Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis.

Authors:  R Balfour Sartor
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2006-07

5.  Monocyte differentiation in intestine-like macrophage phenotype induced by epithelial cells.

Authors:  T Spöttl; M Hausmann; M Kreutz; A Peuker; D Vogl; J Schölmerich; W Falk; R Andreesen; T Andus; H Herfarth; G Rogler
Journal:  J Leukoc Biol       Date:  2001-08       Impact factor: 4.962

6.  Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease.

Authors:  J P Hugot; M Chamaillard; H Zouali; S Lesage; J P Cézard; J Belaiche; S Almer; C Tysk; C A O'Morain; M Gassull; V Binder; Y Finkel; A Cortot; R Modigliani; P Laurent-Puig; C Gower-Rousseau; J Macry; J F Colombel; M Sahbatou; G Thomas
Journal:  Nature       Date:  2001-05-31       Impact factor: 49.962

7.  A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease.

Authors:  Y Ogura; D K Bonen; N Inohara; D L Nicolae; F F Chen; R Ramos; H Britton; T Moran; R Karaliuskas; R H Duerr; J P Achkar; S R Brant; T M Bayless; B S Kirschner; S B Hanauer; G Nuñez; J H Cho
Journal:  Nature       Date:  2001-05-31       Impact factor: 49.962

8.  Induction of human beta-defensin 2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin.

Authors:  Miriam Schlee; Jan Wehkamp; Artur Altenhoefer; Tobias A Oelschlaeger; Eduard F Stange; Klaus Fellermann
Journal:  Infect Immun       Date:  2007-02-05       Impact factor: 3.441

9.  Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis.

Authors:  Daniel Rachmilewitz; Kyoko Katakura; Fanny Karmeli; Tomoko Hayashi; Constantin Reinus; Bernard Rudensky; Shizuo Akira; Kiyoshi Takeda; Jongdae Lee; Kenji Takabayashi; Eyal Raz
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682

10.  Preventive effects of Escherichia coli strain Nissle 1917 on acute and chronic intestinal inflammation in two different murine models of colitis.

Authors:  Michael Schultz; Ulrike G Strauch; Hans-Jörg Linde; Sonja Watzl; Florian Obermeier; Claudia Göttl; Nadja Dunger; Nicole Grunwald; Jürgen Schölmerich; Heiko C Rath
Journal:  Clin Diagn Lab Immunol       Date:  2004-03
View more
  23 in total

1.  Lactobacillus paracasei and Lactobacillus plantarum strains downregulate proinflammatory genes in an ex vivo system of cultured human colonic mucosa.

Authors:  Christine Bäuerl; Marta Llopis; María Antolín; Vicente Monedero; Manuel Mata; Manuel Zúñiga; Francisco Guarner; Gaspar Pérez Martínez
Journal:  Genes Nutr       Date:  2012-06-06       Impact factor: 5.523

2.  Probiotics and Gastrointestinal Disease: Clinical Evidence and Basic Science.

Authors:  Elaine O Petrof
Journal:  Antiinflamm Antiallergy Agents Med Chem       Date:  2009-09-01

3.  CRISPR-based curing and analysis of metabolic burden of cryptic plasmids in Escherichia coli Nissle 1917.

Authors:  Halimatun S Zainuddin; Yanfen Bai; Thomas J Mansell
Journal:  Eng Life Sci       Date:  2019-06-03       Impact factor: 2.678

4.  The probiotic Escherichia coli Nissle 1917 reduces pathogen invasion and modulates cytokine expression in Caco-2 cells infected with Crohn's disease-associated E. coli LF82.

Authors:  Claudia Huebner; Yaoyao Ding; Ivonne Petermann; Christoph Knapp; Lynnette R Ferguson
Journal:  Appl Environ Microbiol       Date:  2011-02-11       Impact factor: 4.792

5.  Therapeutic effects of four strains of probiotics on experimental colitis in mice.

Authors:  Lin Lin Chen; Xue Hong Wang; Yi Cui; Guang Hui Lian; Jie Zhang; Chun Hui Ouyang; Fang Gen Lu
Journal:  World J Gastroenterol       Date:  2009-01-21       Impact factor: 5.742

Review 6.  Probiotics: progress toward novel therapies for intestinal diseases.

Authors:  Fang Yan; David Brent Polk
Journal:  Curr Opin Gastroenterol       Date:  2010-03       Impact factor: 3.287

7.  Role of F1C fimbriae, flagella, and secreted bacterial components in the inhibitory effect of probiotic Escherichia coli Nissle 1917 on atypical enteropathogenic E. coli infection.

Authors:  Sylvia Kleta; Marcel Nordhoff; Karsten Tedin; Lothar H Wieler; Rafal Kolenda; Sibylle Oswald; Tobias A Oelschlaeger; Wilfried Bleiss; Peter Schierack
Journal:  Infect Immun       Date:  2014-02-18       Impact factor: 3.441

8.  Intestinal-borne dermatoses significantly improved by oral application of Escherichia coli Nissle 1917.

Authors:  Elina Manzhalii; Daniel Hornuss; Wolfgang Stremmel
Journal:  World J Gastroenterol       Date:  2016-06-21       Impact factor: 5.742

9.  The K5 capsule of Escherichia coli strain Nissle 1917 is important in mediating interactions with intestinal epithelial cells and chemokine induction.

Authors:  Mohamed Hafez; Kelly Hayes; Marie Goldrick; Geoff Warhurst; Richard Grencis; Ian S Roberts
Journal:  Infect Immun       Date:  2009-04-20       Impact factor: 3.441

10.  Post-translational inhibition of IP-10 secretion in IEC by probiotic bacteria: impact on chronic inflammation.

Authors:  Gabriele Hoermannsperger; Gabriele Hörmannsperger; Thomas Clavel; Micha Hoffmann; Caroline Reiff; Denise Kelly; Gunnar Loh; Michael Blaut; Gabriele Hölzlwimmer; Melanie Laschinger; Dirk Haller
Journal:  PLoS One       Date:  2009-02-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.